Systematic Review: Treatment for Addictive Disorder in Transplant Patients.
Journal
The American journal on addictions
ISSN: 1521-0391
Titre abrégé: Am J Addict
Pays: England
ID NLM: 9208821
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
11
2019
revised:
04
04
2020
accepted:
23
04
2020
pubmed:
16
5
2020
medline:
30
4
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
The number of patients with substance use disorders in need for organ transplantation is expected to increase. Patients with addictive disorders are considered a higher risk of negative outcomes after organ transplantation due to the impact of substance use upon medical status and adherence with treatment. The goal of this systematic review was to assess the current literature on treatment for addiction transplant candidates and recipients. We conducted a literature search within four databases PubMed, MEDLINE, EMBASE, and PsycINFO for publications dated 1/1/1988 to 12/31/2018. Out of 3108 articles identified through database screening, 39 were included in the qualitative synthesis. Sixteen studies described addiction treatment in groups over five patients. All the articles included liver transplant patients, with only two studies including patients who needed a kidney or a heart transplant. Nine articles described treatment of alcohol use disorder exclusively, five focused on treatment of opioid use disorders. Although 9 of 16 studies were prospective, the variability of the treatment intervention, outcome measures, and control group when applicable prohibited a meaningful meta-analysis of the results. Eight articles that described the case reports are analyzed separately. Promising treatment options for alcohol use disorder have been reported but more studies are needed to confirm their effectiveness and their feasibility. Methadone appears effective for opioid disorder in transplant patients. To the best of our knowledge, this is the first systematic review on the treatment of addictive disorders in transplant patients. (Am J Addict 2020;29:445-462).
Sections du résumé
BACKGROUND AND OBJECTIVES
The number of patients with substance use disorders in need for organ transplantation is expected to increase. Patients with addictive disorders are considered a higher risk of negative outcomes after organ transplantation due to the impact of substance use upon medical status and adherence with treatment. The goal of this systematic review was to assess the current literature on treatment for addiction transplant candidates and recipients.
METHODS
We conducted a literature search within four databases PubMed, MEDLINE, EMBASE, and PsycINFO for publications dated 1/1/1988 to 12/31/2018.
RESULTS
Out of 3108 articles identified through database screening, 39 were included in the qualitative synthesis. Sixteen studies described addiction treatment in groups over five patients. All the articles included liver transplant patients, with only two studies including patients who needed a kidney or a heart transplant. Nine articles described treatment of alcohol use disorder exclusively, five focused on treatment of opioid use disorders. Although 9 of 16 studies were prospective, the variability of the treatment intervention, outcome measures, and control group when applicable prohibited a meaningful meta-analysis of the results. Eight articles that described the case reports are analyzed separately.
DISCUSSION AND CONCLUSIONS
Promising treatment options for alcohol use disorder have been reported but more studies are needed to confirm their effectiveness and their feasibility. Methadone appears effective for opioid disorder in transplant patients.
SCIENTIFIC SIGNIFICANCE
To the best of our knowledge, this is the first systematic review on the treatment of addictive disorders in transplant patients. (Am J Addict 2020;29:445-462).
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-462Informations de copyright
© 2020 American Academy of Addiction Psychiatry.
Références
Webb K, Shepherd L, Day E, et al. Transplantation for alcoholic liver disease: report of a consensus meeting. Liver Transpl. 2006;12:301-305. https://doi.org/10.1002/lt.20681
United Network for Organ Sharing (UNOS). Public data from UNOS/OPTN scientific registry. http://www.unos.org. Accessed 1 March 2007.
Anantharaju A, Van Thiel TH. Alcoholic Liver Disease. 8th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 1999:941-971.
Pfitzmann R, Schwenzer J, Rayes N, et al. Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2007;13:197-205. https://doi.org/10.1002/lt.20934
Based on the organ procurement and transplantation network (OPTN) data; 2019. http://optn.transplant.hrsa.gov. Accessed 1 March 2020.
Sirri L, Potena L, Masetti M, et al. Prevalence of substance-related disorders in heart transplantation candidates. Transplant Proc. 2007;39:1970-1972. https://doi.org/10.1016/j.transproceed.2007.05.020
Gueye AS, Chelamcharla M, Baird BC, et al. The association between recipient alcohol dependency and long-term graft and recipient survival. Nephrol Dial Transpl. 2007;22:891-898. https://doi.org/10.1093/ndt/gfl689
DiMartini A, Dew MA, Javed L, et al. Pretransplant psychiatric and medical comorbidity of alcoholic liver disease patients who received liver transplant. Psychosomatics. 2004;45:517-523. https://doi.org/10.1176/appi.psy.45.6.517
Kotlyar DS, Burke A, Campbell MS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol. 2008;103:734-743; quiz 744. https://doi.org/10.1111/j.1572-0241.2007.01691.x
Perut V, Conti F, Scatton O, et al. Might physicians be restricting access to liver transplantation for patients with alcoholic liver disease? J Hepatol. 2009;51:707-714. https://doi.org/10.1016/j.jhep.2009.04.018
Sandhu GS, Khattak M, Woodward RS, et al. Impact of substance abuse on access to renal transplantation. Transplantation. 2011;91:86-93. https://doi.org/10.1097/TP.0b013e3181fc8903
Alali J, Ramji A, Ho JK, et al. Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol. 2006;20:95-99.
Arya A, Hernandez-Alejandro R, Marotta P, et al. Recipient ineligibility after liver transplantation assessment: a single centre experience. Can J Surg. 2013;56:E39-E43. https://doi.org/10.1503/cjs.004512
Koch M, Banys P. Liver transplantation and opioid dependence. JAMA. 2001;285:1056-1058.
Abougergi MS, Rai R, Cohen CK, et al. Trends in adult-to-adult living donor liver transplant organ donation: the Johns Hopkins experience. Prog Transplant. 2006;16:28-32.
Brauer RB, Heidecke C, Beckurts KTE, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int. 1997;10:229-233.
Carrion JA, Escorsell A, Nogue S, et al. [Ecstasy-induced fulminant hepatic failure and emergency liver transplantation]. Med Clin. 2003;121:118-119.
De Carlis L, De Gasperi A, Slim AO, et al. Liver transplantation for ecstasy-induced fulminant hepatic failure. Transplant Proc. 2001;33:2743-2744.
Shibli JA, Marcantonio E, Spolidorio LC, et al. Cocaine associated with onlay bone graft failure: a clinical and histologic report. Implant Dent. 2005;14:248-251.
Cuadrado A, Fabrega E, Casafont F, et al. Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl. 2005;11:420-426. https://doi.org/10.1002/lt.20386
Rice JP, Eickhoff J, Agni R, et al. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl. 2013;19:1377-1386. https://doi.org/10.1002/lt.23762
Faure S, Herrero A, Jung B, et al. Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication. J Hepatol. 2012;57:306-312. https://doi.org/10.1016/j.jhep.2012.03.014
Botha P, Peaston R, White K, et al. Smoking after cardiac transplantation. Am J Transpl. 2008;8:866-871. https://doi.org/10.1111/j.1600-6143.2007.02119.x
Kodali S, Kaif M, Tariq R, et al. Alcohol relapse after liver transplantation for alcoholic cirrhosis-impact on liver graft and patient survival: a meta-analysis. Alcohol Alcohol. 2018;53:166-172. https://doi.org/10.1093/alcalc/agx098
Pageaux GP, Bismuth M, Perney P, et al. Alcohol relapse after liver transplantation for alcoholic liver disease: does it matter? J Hepatol. 2003;38:629-634.
DiMartini A, Javed L, Russell S, et al. Tobacco use following liver transplantation for alcoholic liver disease: an underestimated problem. Liver Tanspl. 2005;11:679-683. https://doi.org/10.1002/lt.20385
DiMartini A, Day N, Dew MA, et al. Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl. 2006;12:813-820. https://doi.org/10.1002/lt.20688
DiMartini A, Dew MA, Day N, et al. Trajectories of alcohol consumption following liver transplantation. Am J Transpl. 2010;10:2305-2312. https://doi.org/10.1111/j.1600-6143.2010.03232.x
Robaeys G, Nevens F, Stärkel P, et al. Previous intravenous substance use and outcome of liver transplantation in patients with chronic hepatitis C infection. Transplant Proc. 2009;41:589-594. https://doi.org/10.1016/j.transproceed.2009.01.003
De Gottardi A, Hilleret MN, Gelez P, et al. Injection drug use before and after liver transplantation: a retrospective multicenter analysis on incidence and outcome. Clin Transplant. 2010;24:564-571. https://doi.org/10.1111/j.1399-0012.2009.01121.x
Fierz K, Steiger J, Denhaerynck K, et al. Prevalence, severity and correlates of alcohol use in adult renal transplant recipients. Clin Transplant. 2006;20:171-178. https://doi.org/10.1111/j.1399-0012.2005.00460.x
De Gottardi A, Spahr L, Gelez P, et al. A simple score for predicting alcohol relapse after liver transplantation: results from 387 patients over 15 years. Arch Intern Med. 2007;167:1183-1188. https://doi.org/10.1001/archinte.167.11.1183
Rustad JK, Stern TA, Prabhakar M, et al. Risk factors for alcohol relapse following orthotopic liver transplantation: a systematic review. Psychosomatics. 2015;56:21-35. https://doi.org/10.1016/j.psym.2014.09.006
Chuncharunee L, Yamashiki N, Thakkinstian A, et al. Alcohol relapse and its predictors after liver transplantation for alcoholic liver disease: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19:150. https://doi.org/10.1186/s12876-019-1050-9
Karim Z, Intaraprasong P, Scudamore CH, et al. Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol. 2010;24:245-250.
Hwang S, Lee SG, Kim KK, et al. Efficacy of 6-month pretransplant abstinence for patients with alcoholic liver disease undergoing living donor liver transplantation. Transplant Proc. 2006;38:2937-2940. https://doi.org/10.1016/j.transproceed.2006.08.139
Gish RG, Lee A, Brooks L, et al. Long-term follow-up of patients diagnosed with alcohol dependence or alcohol abuse who were evaluated for liver transplantation. Liver Transpl. 2001;7:581-587. https://doi.org/10.1053/jlts.2001.25455
Jauhar S, Talwalkar JA, Schneekloth T, et al. Analysis of factors that predict alcohol relapse following liver transplantation. Liver Transpl. 2004;10:408-411. https://doi.org/10.1002/lt.20086
Hartl J, Scherer MN, Loss M, et al. Strong predictors for alcohol recidivism after liver transplantation: non-acceptance of the alcohol problem and abstinence of <3 months. Scand J Gastroenterol. 2011;46:1257-1266. https://doi.org/10.3109/00365521.2011.603160
Kelly M, Chick J, Gribble R, et al. Predictors of relapse to harmful alcohol after orthotopic liver transplantation. Alcohol Alcohol. 2006;41:278-283. https://doi.org/10.1093/alcalc/agh257
Perney P, Bismuth M, Sigaud H, et al. Are preoperative patterns of alcohol consumption predictive of relapse after liver transplantation for alcoholic liver disease? Transpl Int. 2005;18:1292-1297. https://doi.org/10.1111/j.1432-2277.2005.00208.x
Rodrigue J, Hanto D, Curry M. Substance abuse treatment and its association with relapse to alcohol use following liver transplantation. Transpl Int. 2013;2:64. https://doi.org/10.1111/tri.12210
Altamirano J, Bataller R, Cardenas A, et al. Predictive factors of abstinence in patients undergoing liver transplantation for alcoholic liver disease. Ann Hepatol. 2012;11:213-221.
Hanrahan JS, Eberly C, Mohanty PK. Substance abuse in heart transplant recipients: a 10-year follow-up study. Prog Transplant. 2001;11:285-290.
Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candidates: predicting post-transplant hospitalizations, rejection episodes, and survival. Psychosomatics. 2006;47:213-222. https://doi.org/10.1176/appi.psy.47.3.213
Brinkley DM, Novak E, Topkara VK, et al. Graft survival after cardiac transplantation for alcohol cardiomyopathy. Transplantation. 2014;98:465-469. https://doi.org/10.1097/tp.0000000000000083
Eshelman A, Paulson D, Meyer T, et al. The influence of alcohol abuse history on the differential, longitudinal patterns of mental and physical quality of life following liver transplantation. Transplant Proc. 2010;42:4145-4147. https://doi.org/10.1016/j.transproceed.2010.09.022
Chang G, Antin JH, Orav EJ, et al. Substance abuse and bone marrow transplant. Am J Drug Alcohol Abuse. 1997;23:301-308.
Chang G, Orav EJ, Tong MY, et al. Predictors of 1-year survival assessed at the time of bone marrow transplantation. Psychosomatics. 2004;45:378-385. https://doi.org/10.1176/appi.psy.45.5.378
Weinkauf JG, Puttagunta L, Nador R, et al. Long-term outcome of lung transplantation in previous intravenous drug users with talc lung granulomatosis. Transplant Proc. 2013;45:2375-2377. https://doi.org/10.1016/j.transproceed.2012.11.004
DiMartini A, Crone C, Dew MA. Alcohol and substance use in liver transplant patients. Clin Liver Dis. 2011;15:727-751. https://doi.org/10.1016/j.cld.2011.08.002
Lucey MR. Liver transplantation in patients with alcoholic liver disease. Liver Transpl. 2011;17:751-759. https://doi.org/10.1002/lt.22330
Burra P, Senzolo M, Adam R, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transpl. 2010;10:138-148. https://doi.org/10.1111/j.1600-6143.2009.02869.x
Foster PF, Fabrega F, Karademir S, et al. Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology. 1997;25:1469-1477. https://doi.org/10.1002/hep.510250627
Mehra M, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant. 2006;25:1024-1042.
Glannon W. Responsibility, alcoholism, and liver transplantation. J Med Philos. 1998;23:31-49. https://doi.org/10.1076/jmep.23.1.31.2595
Congly SE, Lee SS. Liver transplantation for alcoholic liver disease: a devilish dilemma. Can J Gastroenterol. 2013;27:625-626.
Coignard E, Blanchard B, Jault F, et al. [Alcoholic cardiomyopathy and heart transplantation]. Arch Mal Coeur Vaiss. 1998;91:45-51.
Weinrieb RM, Van Horn DHA, McLellan AT, et al. Alcoholism treatment after liver transplantation: lessons learned from a clinical trial that failed. Psychosomatics. 2001;42:110-116. https://doi.org/10.1176/appi.psy.42.2.110
Weinrieb RM, Van Horn DH, Lynch KG, et al. A randomized, controlled study of treatment for alcohol dependence in patients awaiting liver transplantation. Liver Transpl. 2011;17:539-547. https://doi.org/10.1002/lt.22259
Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011;365:1790-1800. https://doi.org/10.1056/NEJMoa1105703
Addolorato G, Mirijello A, Leggio L, et al. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res. 2013;37:1601-1608. https://doi.org/10.1111/acer.12117
Björnsson E, Olsson J, Rydell A, et al. Long-term follow-up of patients with alcoholic liver disease after liver transplantation in Sweden: impact of structured management on recidivism. Scand J Gastroenterol. 2005;40:206-216.
Coffman KL, Hoffman A, Sher L, et al. Treatment of the postoperative alcoholic liver transplant recipient with other addictions. Liver Transpl Surg. 1997;3:322-327.
DeMartini KS, Schilsky ML, Palmer A, et al. Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study. Alcohol Clin Exp Res. 2018;42:761-769. https://doi.org/10.1111/acer.13603
Erim Y, Böttcher M, Schieber K, et al. Feasibility and acceptability of an alcohol addiction therapy integrated in a transplant center for patients awaiting liver transplantation. Alcohol Alcohol. 2016;51:40-46. https://doi.org/10.1093/alcalc/agv075
Georgiou G, Webb K, Griggs K, et al. First report of a psychosocial intervention for patients with alcohol-related liver disease undergoing liver transplantation. Liver Transpl. 2003;9:772-775.
Hogan BJ, Shepherd E, Webzell I, et al. The UK experience of liver transplantation in patients receiving opiate replacement therapy. Liver Transpl. 2011;1:S122.
Kanchana T. Liver transplantation for patients on methadone maintenance. Liver Transpl. 2002;8:778-782. https://doi.org/10.1053/jlts.2002.33976
Kotz MM, Stowe JA. Addiction relapse prevention in solid-organ transplantation. Transplant Proc. 1999;31:48S-49SS.
Lattanzi B, Attilia ML, Di Gregorio V, et al. Is the multidisciplinary support effective in preventing alcohol relapse after liver transplantation? Dig Liver Dis. 2017;49:e242.
Liu LU, Schiano TD, Lau N, et al. Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transpl. 2003;3:1273-1277.
Lynch MJ, Zimbrean P. Buprenorphine/naloxone for the treatment of opioid use disorder in organ transplantation patients. Am J Addict. 2017;26:268-269. https://doi.org/10.1111/ajad.12545
Masson S, Marrow B, Kendrick S, et al. An “alcohol contract” has no significant effect on return to drinking after liver transplantation for alcoholic liver disease. Transpl Int. 2014;27:475-481.
Rodrigue JR, Hanto DW, Curry MP. Substance abuse treatment and its association with relapse to alcohol use after liver transplantation. Liver Transpl. 2013;19:1387-1395. https://doi.org/10.1002/lt.23747
Weinrieb RM, Barnett R, Lynch KG, et al. A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. Liver Transpl. 2004;10:97-106. https://doi.org/10.1002/lt.20003
Weinrieb RM, O’Brien CP. A case report of naltrexone for alcoholism in a liver transplant recipient: side effects and safety. Am J Addict. 2004;13:495-497.
Siniscalchi A, Piraccini E, Miklosova Z, et al. Opioid-induced hyperalgesia and rapid opioid detoxification after tacrolimus administration. Anesth Analg. 2008;106:645-646.
Hancock MM, Prosser CC, Ransibrahmanakul K, et al. Liver transplant and hepatitis C in methadone maintenance therapy: a case report. Subst Abuse Treat Prev Policy. 2007;2:5. https://doi.org/10.1186/1747-597x-2-5
Piz L, Maremmani AGI, Rugani F, et al. Requiring stabilized heroin addicts to stop successfull agonist opioid treatment before liver transplantation can shift patients over a cross-acting (alcohol) substance abuse. Heroin Addict Relat Clin Probl. 2011;13:35-38.
Rodgman C, Pletsch G. Double successful buprenorphine/naloxone induction to facilitate cardiac transplantation in an iatrogenically opiate-dependent patient. J Addict Med. 2012;6:177-178.
Aldemir E, Coskunol H, Kilic M, et al. Treatment of opioid dependence with buprenorphine/naloxone after liver transplantation: report of two cases. Transplant Proc. 2016;48:2769-2772.
Kimura H, Onishi Y, Kishi S, et al. Successful post-transplant psychiatric interventions during long-term follow-up of patients receiving liver transplants for alcoholic liver disease. Am J Case Rep. 2017;18:1215-1219.
Lee MR, Leggio L. Management of alcohol use disorder in patients requiring liver transplant. Am J Psychiatry. 2015;172:1182-1189.
Cierny GB, Wolf BJ, Stoll WD, et al. Preoperative gabapentin is associated with reduced opioid consumption in laparoscopic donor nephrectomy: a pilot study. Anesth Analg. 2012;1:S364.
Gallay BJ, De Mattos AM, Norman DJ. Reversible acute renal allograft dysfunction due to gabapentin. Transplantation. 2000;70:208-209.
Finch CK, Eason J, Usery JB. Gabapentin withdrawal syndrome in a post-liver transplant patient. J Pain Palliat Care Pharmacother. 2010;24:236-238.
Page RL, Luna M, Brieke A, et al. Low-dose gabapentin for intractable hiccups in a heart transplant recipient. Prog Transplant. 2011;21:340-343.
Pon D, De Guzman Y, Zia A. Incidence of nausea and vomiting (N/V) and rescue antiemetic usage in adult hematopoietic stem cell transplant (HSCT) patients. J Oncol Pharm Practice. 2012;1:17-18.
Sahu S, Karna ST, Agarwal A, et al. Ondansetron causing near fatal catastrophe in a renal transplant recipient. Indian J Anaesth. 2011;55:81-82.
Eisenberg S. Prevention of DMSO-related nausea and vomiting by prophylactic administration of ondansetron for patients receiving autologous cryopreserved peripheral blood stem cells. Biol Blood Marrow Transplant. 2011;1:S194.
Himmelsbach FA, Köhler E, Zanker B, et al. Toxic effect of baclofen in chronic haemodialysis and renal transplantation. Dtsch Med Wochenschr. 1992;117:733-737 (German).
Pratini NR, Neufeld JA. Intrathecal baclofen therapy after liver transplant in a patient with Crigler-Najjar syndrome. PM R. 2014;6:196-198.
Aljassem AHL, Cohn S, et al. Closing Pandora’s box: an evidence based approach to opioid-tolerant patients following transplantation. the case of Iv methadone. Am J Transplant. 2018;18:978-979.
Bajaj JS, Saeian K, Hafeezullah M, et al. Failure to fully disclose during pretransplant psychological evaluation in alcoholic liver disease: a driving under the influence corroboration study. Liver Transpl. 2008;14:1632-1636. https://doi.org/10.1002/lt.21574
Webzell I, Ball D, Bell J, et al. Substance use by liver transplant candidates: an anonymous urinalysis study. Liver Transpl. 2011;17:1200-1204. https://doi.org/10.1002/lt.22370
Allen JP, Wurst FM, Thon N, et al. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl. 2013;19:369-376. https://doi.org/10.1002/lt.23596
Staufer K, Andresen H, Vettorazzi E, et al. Urinary ethyl glucuronide as a novel screening tool in patients pre- and post-liver transplantation improves detection of alcohol consumption. Hepatology. 2011;54:1640-1649. https://doi.org/10.1002/hep.24596
Berlakovich GA, Soliman T, Freundorfer E, et al. Pretransplant screening of sobriety with carbohydrate-deficient transferrin in patients suffering from alcoholic cirrhosis. Transpl Int. 2004;17:617-621. https://doi.org/10.1007/s00147-004-0765-9
Piano S, Marchioro L, Gola E, et al. Assessment of alcohol consumption in liver transplant candidates and recipients: the best combination of the tools available. Liver Transpl. 2014;20:815-822. https://doi.org/10.1002/lt.23881
Beresford TP, Martin B, Alfers J. Developing a brief monitoring procedure for alcohol-dependent liver graft recipients. Psychosomatics. 2004;45:220-223. https://doi.org/10.1176/appi.psy.45.3.220
Haller DL, Acosta MC, Lewis D, et al. Hair analysis versus conventional methods of drug testing in substance abusers seeking organ transplantation. Am J Transpl. 2010;10:1305-1311. https://doi.org/10.1111/j.1600-6143.2010.03090.x
Ehlers SL, Bronars CA, Patten CA, et al. Accuracy of self-reported tobacco use status among hematopoietic SCT patients. Bone Marrow Transplant. 2014;49:961-965. https://doi.org/10.1038/bmt.2014.70
Allen JP, Wurst FM, Thon N, et al. Assessing the drinking status of liver transplant patients with alcoholic liver disease. Liver Transpl. 2013;19:369-376. https://doi.org/10.1002/lt.23596
Chandok N, Aljawad M, White A, et al. Liver transplantation for alcoholic liver disease among Canadian transplant centres: a national study. Can J Gastroenterol. 2013;27:643-646.
Immonen JA, Zagon IS, McLaughlin PJ. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing. Exp Biol Med. 2014;239:1300-1309. https://doi.org/10.1177/1535370214543061
Jingxue W, Yifan L, Li S. The suppressive effect of naltrexone on transplantation rejection. Chin J Microbiol Immunol. 1997;17:107-110 (Chinese).
Grossmann KF, Blankenship MB, Akerley W, et al. A phase I clinical study investigating disulfiram and copper gluconate in patients with advanced treatment-refractory solid tumors involving the liver. Cancer Res. 2011;1. https://doi.org/10.1158/1538-7445.AM2011-1308
Joyal JL, Hillier SM, Tesson M, et al. Disulfiram combines with [131I]MIP-1466, a small molecule prostate-specific membrane antigen (PSMA) inhibitor, to enhance prostate cancer radiotherapy. Eur J Nucl Med Mol Imaging. 2012;39:S327-S328. https://doi.org/10.1007/s00259-012-2222-9
Liu P, Wang Z, Brown S, et al. Disulfiram-an anti-alcoholism medicine giving breast cancer patients new hope. Anticancer Res. 2014;34:6240-6241.
Stowe J, Kotz M. Addiction medicine in organ transplantation. Prog Transplant. 2001;11:50-57.
Wagner CC, Haller DL, Olbrisch ME. Relapse prevention treatment for liver transplant patients. J Clin Psychol Med Settings. 1996;3:387-398. https://doi.org/10.1007/bf01994021
Weinrieb RM, Van Horn DH, McLellan AT, et al. Drinking behavior and motivation for treatment among alcohol-dependent liver transplant candidates. J Addict Dis. 2001;20:105-119. https://doi.org/10.1300/J069v20n02_09
López-Navas A, Ríos A, Moya-Faz FJ, et al. Emotional-type psychopathologic symptoms among patients with terminal chronic alcohol-induced liver cirrhosis. Transplant Proc. 2012;44:1510-1512. https://doi.org/10.1016/j.transproceed.2012.05.021
DeMartini KS, Schilsky ML, Palmer A, et al. Text messaging to reduce alcohol relapse in prelisting liver transplant candidates: a pilot feasibility study. Alcohol Clin Exp Res. 2018;42:761-769. https://doi.org/10.1111/acer.13603
Addolorato G, Mirijello A, Leggio L, et al. Liver transplantation in alcoholic patients: impact of an alcohol addiction unit within a liver transplant center. Alcohol Clin Exp Res. 2013;37:1601-1608. https://doi.org/10.1111/acer.12117
Furlan V, Hafi A, Dessalles MC, et al. Methadone is poorly removed by haemodialysis. Nephrol Dial Transpl. 1999;14:254-255.
Lau EM, McCaughan G, Torzillo PJ. Improvement in hepatopulmonary syndrome after methadone withdrawal: a case report with implications for disease mechanism. Liver Transpl. 2010;16:870-873. https://doi.org/10.1002/lt.22081
Effective Medical Treatment of Opiate Addiction. National consensus development panel on effective medical treatment of opiate addiction. JAMA. 1998;280:1936-1943.
Ehlers SL, Rodrigue JR, Patton PR, et al. Treating tobacco use and dependence in kidney transplant recipients: development and implementation of a program. Prog Transplant. 2006;16:33-37.